Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
According to Fortune Business Insights, the launch of new PCR-based detection techniques will lead to a surge in demand for PCR instruments in the coming years
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Recall does not include any metabolic deficiency nutrition formulas
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Agilent will integrate the technology into its lab informatics platforms, enabling customers to automate GC/MS data analysis
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
TRIS AMINO HCl is widely used as a diagnostic reagent and as a downstream processing buffer in the purification of commercial biopharmaceuticals
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
Subscribe To Our Newsletter & Stay Updated
